Celltrion Makes Progress On Coronavirus Treatment
Also Plans To Launch Rapid Self-Testing Diagnostic Kit
Executive Summary
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
You may also be interested in...
Celltrion Will Trial COVID-19 Antiviral From July
Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.
Celltrion Pledges Efforts on Coronavirus Antibody And Kit
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
Nippon Chemiphar Is Managing To Slow Its Decline
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: